“…Technical advances in the past decade have broadened its applicability to see it become a suitable, and often popular, treatment option for previously challenging small and mobile tumours or non-oncologic pathologies. An emerging application is stereotactic arrhythmic radioablation (STAR) (Loo et al, 2015, Zei andSoltys, 2017) with preclinical animal studies (Blanck et al, 2014, Bode et al, 2015, Maguire et al, 2011, Sharma et al, 2010, Lehmann et al, 2016, treatment planning studies (Blanck et al, 2016, Ipsen et al, 2014, Xia et al, 2016, Gardner and Weidlich, 2016, and developing human clinical studies (Cvek et al, 2014, Loo et al, 2015, Zei and Soltys, 2017, Cuculich et al, 2017 suggesting that stereotactic radiosurgery could be an effective and safe treatment 10 for ventricular tachycardia and atrial fibrillation (AF).…”